EC Technology Spółka z Ograniczoną Odpowiedzialnością w Likwidacji (KRS 0000740908, NIP 9910521172) is a Polish company, headquartered in Krasiejów, Opolskie voivodeship. EC TECHNOLOGY SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ W LIKWIDACJI operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since July 23, 2018. EC TECHNOLOGY SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ W LIKWIDACJI's most recently reported net revenue was 0 PLN for 2024.
Entity dissolved
The data shown reflects the last known state before removal.
Historical suspension of activities
Suspension: December 30, 2019 - resumed: December 31, 2021
Negative equity
Negative equity in 6 of 6 available reporting years.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile (archived data) - EC Technology
Identity
- Name
- EC Technology Spółka z Ograniczoną Odpowiedzialnością w Likwidacji
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- July 23, 2018
- Registry status as of
- July 13, 2026
- Latest entry
- July 13, 2026
- Founding act
- 06.07.2018R.
Articles of association history (1)
- July 6, 2018: 06.07.2018R.
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Last known registered address
Archived data - last known state
- Address
- UL. ZAMOŚCIE, 4, 46-040, KRASIEJÓW, POLSKA
- Voivodeship
- OPOLSKIE
- District
- OPOLSKI
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
Risk and payment profile - EC Technology
Credibility rating
1 / 100
Very poor credibility
Insolvency risk
closed
Significant formal threat
Closure risk
99
/ 100
Extremely high risk
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/8 yrs
Board changes
1
1/8 yrs
PKD changes
0
0/8 yrs
Name changes
1
1/8 yrs
Data from 8 years of registry activity.
Credibility history
Payment reliability score from 2019–2024
Current: F (1/100)
Trend: stable (0.0 pts/year)
Spółka została rozwiązana lub wykreślona z rejestru – wskaźnik wiarygodności płatniczej nie ma już zastosowania. Nie należy podejmować nowej współpracy handlowej z podmiotem nieistniejącym.
Trade credit limit history
Standard limit from 2019–2024
Current: 0 PLN
Safe: 0 PLN
Operational status - EC Technology
Status as of the last registry entry
Founded
July 23, 2018
7 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
KRASIEJÓW
OPOLSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
5.0 K PLN
100 shares total
Shareholders
2
shareholders
Board
N/A
Filed years
6 years
2019–2024 · profitable: 0/6
Registry entries
22
latest: July 13, 2026
Risk signals
Revenue
0 PLN
2024
Net profit
0 PLN
2024
Assets
0 PLN
2024
Equity
-10.7 K PLN
2024
Valuation
0 PLN
closed
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - EC Technology.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
